described that although combination therapy with TRAIL and other compounds could make human colon cancer HCT116 cell line susceptible to TRAIL, Bax-deficient cells but not Bak-deficient cells, restored their resistance to TRAIL (50). The gene discussed is TNFSF10; the disease is malignant colon neoplasm.